Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Hennion & Walsh Asset Management Inc. acquired a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 259,980 shares of the company’s stock, valued at approximately $611,000. Hennion & Walsh Asset Management Inc. owned 0.10% of Autolus Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $43,000. Capstone Investment Advisors LLC acquired a new position in Autolus Therapeutics in the 3rd quarter worth about $51,000. Herbst Group LLC acquired a new position in Autolus Therapeutics in the 3rd quarter worth about $91,000. China Universal Asset Management Co. Ltd. raised its holdings in Autolus Therapeutics by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after purchasing an additional 14,959 shares during the period. Finally, Bellevue Group AG raised its holdings in Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $2.22 on Tuesday. The business has a 50 day simple moving average of $2.67 and a two-hundred day simple moving average of $3.55. Autolus Therapeutics plc has a 12 month low of $2.07 and a 12 month high of $7.37. The stock has a market capitalization of $590.72 million, a P/E ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the business earned ($0.26) earnings per share. As a group, research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AUTL shares. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.